Neuphoria Therapeutics (STU:B1N0) Cash-to-Debt : 31.80 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Neuphoria Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2024 was 31.80.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Neuphoria Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Neuphoria Therapeutics's Cash-to-Debt or its related term are showing as below:

STU:B1N0' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: 2.35 Max: 52.52
Current: 31.82

During the past 13 years, Neuphoria Therapeutics's highest Cash to Debt Ratio was 52.52. The lowest was 0.37. And the median was 2.35.

STU:B1N0's Cash-to-Debt is ranked better than
67.63% of 1486 companies
in the Biotechnology industry
Industry Median: 6.45 vs STU:B1N0: 31.82

Neuphoria Therapeutics Cash-to-Debt Historical Data

The historical data trend for Neuphoria Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Neuphoria Therapeutics Cash-to-Debt Chart

Neuphoria Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash-to-Debt

Get a 7-Day Free Trial

0.37

32.85

48.43

31.20

46.11

Neuphoria Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															31.20	N/A	9.46	46.11	31.80

Competitive Comparison of Neuphoria Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Neuphoria Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Cash-to-Debt falls into.

Neuphoria Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Neuphoria Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.713	/	(0.144	+	0.11)
	=	46.11

Neuphoria Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.282	/	(0.149	+	0.08)
	=	31.80

Neuphoria Therapeutics (STU:B1N0) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Neuphoria Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (STU:B1N0) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BNOX:USA B1N0:Germany

Address

200 Greenhill Road, Eastwood, SA, AUS, 5063

Website

https://www.bionomics.com.au

Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.

Neuphoria Therapeutics Headlines

No Headlines